SEARCH

SEARCH BY CITATION

References

  • 1
    Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005; 365: 15365.
  • 2
    McDonald JS. Adjuvant therapy of colorectal cancer. CA Cancer J Clin 1999; 49: 20219.
  • 3
    Chawla AK, Kachnic LA, Clark JW, Willett CG. Combined modality therapy for rectal and colon cancer. Semin Oncol 2003; 30: 10112.
  • 4
    Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? Intern Med J 2003; 33: 11924.
  • 5
    Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo A, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, van Cutsem E, Brouwers M, Charette M, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 340819.
  • 6
    Figueredo A, Charette M, Maroun J, Brouwers M, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22: 3395407.
  • 7
    Wein A, Hahn EG, Merkel S, Hohenberger W. Adjuvant chemotherapy for stage II (Dukes'B) colon cancer: too early for routine use. Eur J Surg Oncol 2000; 26: 7302.
  • 8
    Mamounas EP. Adjuvant chemotherapy for stage II colon cancer: the time has come. Eur J Surg Oncol 2000; 26: 7259.
  • 9
    Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet, in press.
  • 10
    Cascinu S, Georgoulias V, Kerr D, Maughan T, Labianca R, Ychou M. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. Ann Oncol 2003; 14: 259.
  • 11
    Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes'B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003; 14: 102638.
  • 12
    Menon AG, van Rhihn CM, Morreau H, Putter H, Tollenaar RAEM, van de Velde CJH, Fleuren GJ, Kuppen PJK. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004; 84: 493501.
  • 13
    Kienle P, Koch M. Minimal residual disease in gastrointestinal cancer. Semin Surg Oncol 2001; 20: 28293.
  • 14
    Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T, Herfarth Ch, von Knebel Doeberitz M. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res 1998; 4: 3438.
  • 15
    Weitz J, Kienle P, Magener A, Koch M, Schrödel A, Willeke F, Autschbach F, Lacroix J, Lehnert T, Herfarth Ch, von Knebel Doeberitz M. Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. Clin Cancer Res 1999; 5: 18306.
  • 16
    Weitz J, Koch M, Kienle P, Schrödel A, Willeke F, Benner A, Lehnert T, Herfarth Ch, von Knebel Doeberitz M. Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer. Ann Surg 2000; 232: 6672.
  • 17
    Kienle P, Koch M, Autschbach F, Benner A, Treiber M, Wannenmacher M, von Knebel Doeberitz M, Büchler MW, Herfarth Ch, Weitz J. Decreased detection rate of disseminated tumor cells of rectal cancer patients after preoperative chemoradiation—a first step towards a molecular surrogate marker for neoadjuvant treatment in colorectal cancer. Ann Surg 2003; 238: 3244.
  • 18
    Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U, Henne-Bruns D, Kremer B, Kalthoff H. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res 1997; 57: 310610.
  • 19
    Vogel I, Kalthoff H. Disseminated tumor cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch 2001; 439: 10917.
  • 20
    Sobin LH, Wittekind C. UICC: TNM-classification of malignant tumors. London: Wiley, 1997.
  • 21
    Koch M, Weitz J, Kienle P, Benner A, Willeke F, Lehnert T, Herfarth Ch, von Knebel Doeberitz M. Comparative analysis of tumor cell dissemination in mesenteric, central and peripheral venous blood in patients with colorectal cancer. Arch Surg 2001; 136: 859.
  • 22
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 23
    Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187220.
  • 24
    Merkel S, Wein A, Günther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with stage II colon carcinoma. Cancer 2001; 92: 143543.
  • 25
    Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K. Comparative efficacy of adjuvant chemotherapy in patients with Dukes'B versus Dukes'C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 134955.
  • 26
    Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond EH, Henson DE, Hutter P, Nagle RB, Nielsen ML, Sargent DJ, et al. Prognostic factors in colorectal cancer. Arch Pathol Lab Med 2000; 124: 97994.
  • 27
    Lindemann F, Schlimock G, Dirschedl P, Witte J, Riethmüller G. Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet 1992; 340: 6859.
  • 28
    Vlems FA, Wobbes T, Punt CJ, Van Muijen GN. Detection and clinical relevance of tumor cells in blood and bone marrow of patients with colorectal cancer. Anticancer Res 2003; 23: 52330.
  • 29
    Weiss L. Metastatic inefficiency. Adv Cancer Res 1990; 54: 159211.
  • 30
    Fidler IJ. The biology of human cancer metastasis. Acta Oncol 1991; 30: 66975.
  • 31
    Guller U, Zajac P, Schnider A, Bösch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 76876.
  • 32
    Bessa X, Pinol V, Castelli-Bel S, Piazuelo E, Lacy AM, Elizalde JI, Pique JM, Castells A. Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated for cure. Ann Surg 2003; 237: 36875.
  • 33
    Bessa X, Elizalde JI, Boix L, Pinol V, Lacy AM, Salo J, Pique JM, Castells A. Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. Gastroenterology 2001; 120: 108492.
  • 34
    Bosch B, Guller U, Schnider A, Maurer R, Harder F, Metzger U, Marti WR. Perioperative detection of disseminated tumor cells is an independent prognostic factor in patients with colorectal cancer. Br J Surg 2003; 90: 8828.
  • 35
    LeVoyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21: 29129.
  • 36
    Fidler IJ. Metastasis. Quantitative analysis of distribution and fate of tumor emboli labelled with 125 I-5-iodo-2′deoxyuridine. J Natl Cancer Inst 1970; 45: 77382.
  • 37
    Patel H, LeMarer N, Wharton RQ, Khan ZAJ, Araia R, Glover C, Henry MM, Allen-Mersh TG. Clearance of circulating tumor cells after excision of primary colorectal cancer. Ann Surg 2002; 235: 22631.
  • 38
    Pantel K, Schlimok G, Braun S, Kutter D, Schaller G, Funke I, Izbicki J, Riethmüller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 141924.